Some cancer cells contains Alzheimer cells too: Study

Image
ANI Washington D.C. [USA]
Last Updated : Oct 08 2016 | 11:22 AM IST

A recent study suggests that certain cancer progression proteins and metastasis are stored as amyloid bodies in dormant cancer cells.

Once the amyloid bodies disaggregate, the cancer cells become active again.

Amyloid bodies are known to play a role in the development of neurological diseases such as Alzheimer's and Parkinson's disease but their contributions to the progression of cancer have been largely unknown.

This discovery points to a new avenue for the treatment of various types of cancers by applying knowledge gained from neuroscience to tumor biology.

The author of the study Stephen Lee said, "The amyloid state of protein organization is typically associated with debilitating human neuropathies and rarely observed in physiology,"

Adding, "Yet, we found that a large number of proteins are stored as amyloid bodies in cancer cells that are dormant. The heat shock chaperone pathway can disaggregate the amyloid bodies and turn the dormant cancer cells into active, progressing cancer cells."

The team found that ribosomal intergenic non-coding RNA regulates the process of amyloid formation in cancer cells, making it a target for drug discovery and development.

"If we can stop the amyloid bodies from disaggregating in cancer cells, the hope is that they will remain dormant indefinitely. In addition, we may also be able to turn active cancer cells into dormant ones by encouraging them to store the proteins as amyloid bodies," Lee said.

Amyloidogenesis enables cells to remain viable during prolonged periods of extracellular stress, highlighting the non-toxic and protective nature of the process, not just in cancer cells.

"Following this approach, we wouldn't necessarily rid the body of cancer cells, but we would keep them inactive - shut off, if you will- and not allow them to become active againI am optimistic this could become a novel way of treating cancer. There are already drugs on the market, and others are being studied, that target the ribosomal intergenic noncoding RNA as well as the heat shock chaperone pathway," he said.

The findings were published in the journal Developmental Cell today.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 08 2016 | 10:45 AM IST

Next Story